News Release

Health of young people with ulcerative colitis at risk as most stop taking medication within a year

Peer-Reviewed Publication

Imperial College London

Imperial College Academic Health Science News Release

For immediate release:

Tuesday 12 September 2023

Health of young people with ulcerative colitis at risk as most stop taking medication within a year

Nearly 70 per cent of adolescents and young adults with ulcerative colitis stop taking medication to treat the disease within a year of diagnosis.

Ulcerative colitis is an inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in the intestine, and it affects around 200,000 people in the UK. Failure to take medication to treat the disease can result in frequent relapses, severe disease, and higher risk of colon cancer. It can also lead to a reduced quality of life and higher healthcare costs to treat complications, such as through surgery.

The findings come from a study published in the British Journal of General Practice, led by researchers at Imperial College London, University College London and St George’s University London. 
They found that a quarter of adolescents and young adults with ulcerative colitis discontinued their treatment after one month and 69 per cent within a year of diagnosis. They also found that residents in deprived postcodes were more likely to discontinue treatment compared to those who live in more affluent postcodes, something they suggest may be related to the cost of prescriptions.

The findings of the study may mean that adolescents and young adults diagnosed with ulcerative colitis are at risk of early relapse as not taking medication as prescribed, known as non-adherence, is associated with a five-fold risk of disease relapse compared to those whose adherence is over 80 per cent.

The researchers say the results show that the first year of starting lifelong therapies amongst individuals diagnosed with ulcerative colitis is a critical window to improve adherence for adolescents transitioning to young adulthood and those from deprived postcodes. They suggest that these patients should be actively followed up by GPs to see if they are taking their medications and if they can afford them, as well as discuss with them what to do if symptoms stop and start. They also suggest that alerts should be placed on health records to remind GPs to review these patients.

The study is one of the largest population-based cohort studies of new cases of ulcerative colitis in adolescents and young people. It was funded by the National Institute for Health and Care Research (NIHR) Imperial Biomedical Research Centre and supported by the NIHR Applied Health Research (ARC) programme for Northwest London and NIHR School for Public Health Research.

Professor Sonia Saxena, Professor of Primary Care and Director of the Imperial Child Health Unit in the School of Public Health at Imperial College London, said:

“Ulcerative colitis is a condition that is rising globally in younger populations. If left untreated, young people could suffer with symptoms such as diarrhoea, abdominal pain or even seeing blood in their stool for years.  Alternatively, there may be active inflammation in the gut that does not result in symptoms or visible signs but still causes damage.

“There are therapies that can put the condition into remission if taken as prescribed. However, our study shows that many adolescents and young adults are stopping their medication within a year of being diagnosed. This is concerning as they are at risk of their condition returning and further complications. It can also lead to severe complications such as surgery to remove part of the gut.

“As doctors, this study shows we need to be keeping a close eye on patients particularly within that first year of starting medication. We should check if these patients are getting their medications and whether they have difficulty paying for them, We should also use the opportunity to talk through any recurring symptoms and how to access advice from  providers such as a nurse specialist. I know that this is extra work for very busy clinicians, so it is important that support groups also help get this message out to those young people with ulcerative colitis.”

Ulcerative colitis affects around 200,000 people in the UK. Typical symptoms include diarrhoea, rectal bleeding and abdominal pain. The condition can develop at any age but is most often diagnosed in people between 15 and 25 years old. Globally, new cases of this inflammatory bowel condition are rising in younger populations.

Drugs called 5-aminosalicylic acids (5-ASAs) are used to treat ulcerative colitis. They help prevent flare ups and reduce inflammation. International guidelines recommend that 5-ASA treatment should start promptly after diagnosis and continue long-term to maintain remission. However, estimates suggest medication adherence rates in young people are lower than in adults with IBD and far less is known about the extent and timing of discontinuation.

Researchers wanted to determine rates and risk factors for discontinuation and adherence to oral 5-ASAs in children and young adults in primary care. They analysed data from the UK Clinical Practice Research Datalink of 607 children and young adults aged 10-24 diagnosed with ulcerative colitis between 1998 and 2016. They analysed the number of individuals who started oral 5-ASAs maintenance treatment within six months of their recorded diagnosis date and followed up cases for one year. They also used socio-demographic factors such as sex, age and a postcode-based measure of socioeconomic deprivation called the Index of Multiple Deprivation (IMD) to identify potential predictors of discontinuation and adherence.

The team found that a quarter discounted treatment after one month and 69 percent of individuals discontinued within a year of starting. Discontinuation was higher among those aged 18-24 years (74 per cent) than young groups –10-14 (61 per cent) and 15-17 (56 per cent). The researchers suggest the higher risk of treatment discontinuation and poor adherence during the transition from adolescence to adulthood may be explained by the loss of support from caregivers who encourage adherence in adolescents and provide financial and practical support. 

The team also found that individuals in deprived postcodes were more likely to discontinue treatment compared to those who live in affluent postcodes. The researchers suggest that monthly prescriptions costs may be a factor to low adherence in more deprived postcodes.

The team plan to carry out a further study to understand more about the reasons for low adherence to medication. 


For more information contact:

Maxine Myers (she/her) 
AHSC Communications Manager 
Communications Division 
Imperial College London 
Tel: +44 (0) 7561 451 724 
Duty press officer mobile: +44 (0) 7803 886 248 


About Imperial College Academic Science Centre

The AHSC is a partnership between Imperial College London, The Institute of Cancer Research (ICR) Imperial College Healthcare NHS Trust, Chelsea and Westminster NHS Foundation Trust and the Royal Marsden NHS Foundation Trust, based in West London.

Established in 2007, it was the first AHSC to be created in the UK and was formally designated by the Department of Health in 2009. 

The partnership brings together multi-disciplinary research and education from across all faculties at the College with the resources and critical mass of the three Trusts to advance discovery and innovation within healthcare. 

The purpose of Imperial College AHSC is to utilise excellence in research and education to transform health outcomes, and support the UK's globally competitive position in healthcare related industries by increasing societal and economic gain. 

The AHSC is nested within Imperial College Health Partners, the Academic Health Science Network for North West London, which will ensure that discoveries and innovations are applied on a national and global scale. 

About Imperial College London 

Imperial College London is a global top ten university with a world-class reputation. The College's 22,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering and business. 

The Research Excellence Framework (REF) 2021 found that it has a greater proportion of world-leading research than any other UK university, it was named University of the Year 2022 according to The Times and Sunday Times Good University Guide, University of the Year for Student Experience 2022 by the Good University Guide, and awarded a Queen's Anniversary Prize for its COVID-19 response. 

National Institute for Health and Care Research (NIHR)

The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by:

  • Funding high quality, timely research that benefits the NHS, public health and social care;
  • Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services;
  • Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research;
  • Attracting, training and supporting the best researchers to tackle complex health and social care challenges;
  • Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system;
  • Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries.

NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK Aid from the UK government. 



Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.